Unveiling Progress: Clinical Trial Design & Strategic Insights from Phase 2 Clinical Program in IPF

Time: 2:00 pm
day: Day Two Track B PM

Details:

• Exploring the intricacies of the clinical trial design for AK3280 in IPF, including patient selection criteria, endpoint selection, and the overall study methodology

• How the trial design addresses the unique challenges posed by IPF in the Chinese patient population, showcasing adaptations made to enhance efficacy and relevance

• Insights into the regulatory landscape in China for IPF therapeutics, and innovative strategies employed to streamline regulatory processes

Speakers: